Monographie - Verapamil hydrochloride

Utolsó frissítés :
19/11/2024

Verapamil hydrochloride

Kémiai szerkezet

Kereskedelmi név

A kereskedelmi név meghatározó jelentőségű: a készítmények összetétele országonként, előállítóként eltérő lehet

Calaptin	India
Calovera	India
Cordilox	Nagy-Britannia
Dilacoran	Mexikó
Filacard	Németország
Flamon	Svájc
Geangin	Dánia
Isocor	Románia
Isoptin	Amerikai Egyesült Államok, Ausztrália, Ausztria, Egyiptom, Görögország, Hollandia, Lengyelország, Németország, Olaszország, Portugália, Svájc, Svédország, Szaúd-Arábiában, új-Zéland
Isoptina	Chile
Isoptine	Belgium, Franciaország, Luxemburg
Izoptomil	Egyiptom
Lekoptin	Irán
Manidon	Spanyolország
Palyuan	Mexikó
Securon	Nagy-Britannia
Serriten	Mexikó
Unimylo	Mexikó
Vasolan	Japán
Verahexal	Németország
Veraloc	Dánia
Veramex	Németország
Verapabene	Ausztria
Verapam	Svájc
Verapamil	Amerikai Egyesült Államok, Kanada, Magyarország, Németország, Svédország
Verapamilo	Argentína, Chile, Colombia, Ecuador, Peru
Verpamil	Finnország, Malaysia

Irodalom : Verapamil hydrochloride

	Type	publikáció
62	Napló	Pugh CB, Pabis DJ, Rodriguez C. Visual compatibility of morphine sulfate and meperidine hydrochloride with other injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 123-125.
191	Napló	Riley CM. Stability of milrinone and digoxin, furosemide, procainamide hydrochloride, propranolol hydrochloride, quinidine gluconate, or verapamil hydrochloride in 5% dextrose injection. Am J Hosp Pharm 1988 ; 45: 2079-2091.
242	Napló	Campbell S, Nolan PE, Bliss M, Wood R, Mayersohn M. Stability of amiodarone hydrochloride in admixtures with other injectable drugs. Am J Hosp Pharm 1986 ; 43: 917-921.
288	Napló	Cervenka P, Dejong DJ, Butler BL, Monzingo MD. Visual compatibility of injectable ciprofloxacin lactate with selected injectable drugs during simulated Y-site administration. Hosp Pharm 1992 ; 27: 957-958,961-962.
300	Napló	Trissel LA, Gilbert DL, Martinez JF. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
364	Napló	Johnson CE, Lloyd CW, Mesaros JL, Rubley GJ. Compatibility of aminophylline and verapamil in intravenous admixtures. Am J Hosp Pharm 1989 ; 46: 97-100.
371	Napló	Thompson DF, Stiles ML, Allen LV, Tu YH. Compatibility of verapamil hydrochloride with penicillin admixtures during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 142-145.
372	Napló	Johnson CE, Lloyd CW, Aviles AI, Rybarz KL. Compatibility of premixed theophylline and verapamil intravenous admixtures. Am J Hosp Pharm 1988 ; 45: 609-612.
398	Napló	Jay GT, Fanikos J, Souney PF. Visual compatibility of famotidine with commonly used critical-care medications during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 1556-1557.
660	Napló	Michaels MR, Stauffer GL, Haas DP. Propofol compatibility with other intravenous drug products - Two new methods of evaluating IV emulsion compatibility. Ann Pharmacotherapy 1996 ; 30: 228-232.
706	Napló	Cutie MR. Compatibility of verapamil hydrochloride with other additives. Am J Hosp Pharm 1981 ; 38: 231.
921	Napló	Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292.
1041	Napló	Hasegawa GR, Eder JF. Visual compatibility of dobutamine hydrochloride with other injectable drugs. Am J Hosp Pharm 1984 ; 41: 949-951.
1045	Napló	Das Gupta V, Stewart KR. Stability of dobutamine hydrochloride and verapamil hydrochloride in 0.9% sodium chloride and 5 % dextrose injections. Am J Hosp Pharm 1984 ; 41: 686-689.
1057	Napló	Cutie MR. Compatibility of verapamil hydrochloride injection with commonly used additives. Am J Hosp Pharm 1983 ; 40: 1205-1207.
1098	Napló	Cutie MR. Verapamil precipitation. Ann Intern Med 1983 ; 98: 672.
1099	Napló	Tucker R, Gentile JF. Precipitation of verapamil in an intravenous line. Ann Intern Med 1984 ; 101: 880.
1100	Napló	Bar-Or D, Kulig K, Marx JA, Rosen P. Precipitation of verapamil. Ann Intern Med 1982 ; 97: 619.
1232	Napló	Beatson C, Taylor A. A physical compatibility study of furosemide & flucloxacillin injections. Br J Pharm Pract 1987 ; 9: 223-226, 236.
1351	Napló	Tucker R, Gentle JF. Precipitation of verapamil with nafcillin. Am J Hosp Pharm 1984 ; 41: 2588.
1508	Napló	Voirol P, Berger-Gryllaki M, Pannatier A, Eggimann P, Sadeghipour F. Visual compatibility of insulin aspart with intravenous drugs frequently used in ICU. EJHP 2015 ;22:123-124.
1625	Napló	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1662	Napló	Trissel LA, Saenz CA, Ingram DS, Ogundele AB. Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs. J Oncol Pharm Practice 2002 ; 8: 33-37.
1712	Napló	Trissel LA, Saenz CA. Compatibility screening of Precedex during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 230-233.
1713	Napló	Trissel LA, Saenz CA. Compatibility screening of bivalirudin during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 311-315.
1721	Napló	Trissel LA, Williams KY, Baker MB. Compatibility screening of Hextend during simulated Y-site administration with other drugs. Int J Pharm Compound 2001 ; 5: 69-72.
1803	Napló	Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB. Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2003 ; 60: 80-85.
1925	Napló	Trissel LA , Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.
1944	Napló	Hartman CA, Faria CE, Mago K. Visual compatibility of bivalirudin with selected drugs. Am J Health-Syst Pharm 2004 ; 61: 1774.
1964	Napló	Hartman CA, Baroletti SA, Churchill WW et al. Visual compatibility of argatroban with selected drugs. Am J Health-Syst Pharm 2002 ; 59: 1784-1785.
2018	Napló	Veggeland T. Visual compatibility of clonidine with selected drugs. Am J Health-Syst Pharm 2005 ; 62: 1968-1969.
2087	Napló	Ferreira E, Forest JM, Hildgen P. Compatibility of dimenhydrinate injectable by Y administration. Pharmactuel 2004 ; 37: 17-20.
2090	Napló	Pere H, Chasse V, Forest JM, Hildgen P. Compatibility of injectable pantoprazole in Y-site administration. Pharmactuel 2004 ; 37: 193-196.
2328	Laboratórium	Sugammadex (Bridion®) – Résumé des caractéristiques du produits Organon 2009
3766	Napló	Forrest J.M, Hildgen P. Compatibilité de l’acétylcystéine injectable lors de son administration en Y avec d’autres médicaments usuels Pharmactuel 2014 ; 47, 3 : 161-165.
3824	Napló	Boudi S, Roy H, Forest JM, Leclair G. Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y. Pharmactuel 2023 2023;56,3:91-98
3934	Laboratórium	Eptifibatide (Integrilin®) - Résumé des caractéristiques du produit GlaxoSmithKline Laboratoire 2016
4130	Napló	Koller AK, Krebs S, Dörje F. Untersuchungen zur Kompatibilität von Clonidin mit häufig eingesetzen Arzneimittel auf Intensivstationen. Pharmaceutics 2021 , 13, 21.
4603	Napló	Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G. Compatibility of Lactated Ringer’s Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration. Hosp Pharm 2021 ; 56, 4: 228-234.
4742	Napló	Macoviciuc M, Nguyen C, Forest J-M, Leclair G. Compatibilité physique de l’acétaminophène injectable avec 102 autres médicaments lors d’une administration en Y. Pharmactuel 2022 ; 55, 4: 247-255.

Mentions Légales